According to the official website of the Beijing Drug Administration, the Beijing Drug Administration held a half-year working meeting in August. In the first half of 2024, the Beijing Drug Administration issued the country's first stem cell “Pharmaceutical Production License”. A search on the website of the Beijing Drug Administration revealed that the stem cell company that obtained the first license to produce stem cell drugs in the country is Bosheng Excellent Biotechnology Co., Ltd., which was issued on May 30, 2024, and is valid until May 29, 2029. A search on the official website of the Drug Evaluation Center of the China Drug Administration revealed that the company's stem cell drug declaration indications are: acute graft-versus-host disease where hormone therapy has failed.

According to the official website of the Beijing Drug Administration, the Beijing Drug Administration held a half-year working meeting in August. In the first half of 2024, the Beijing Drug Administration issued the country's first stem cell “Pharmaceutical Production License”. A search on the website of the Beijing Drug Administration revealed that the stem cell company that obtained the first license to produce stem cell drugs in the country is Bosheng Excellent Biotechnology Co., Ltd., which was issued on May 30, 2024, and is valid until May 29, 2029. A search on the official website of the Drug Evaluation Center of the China Drug Administration revealed that the company's stem cell drug declaration indications are: acute graft-versus-host disease where hormone therapy has failed.